Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 11
GLP-1 Receptor Agonists in Psoriasis
Research on GLP-1 receptor agonists in psoriasis is promising but limited. Here is what current reviews and a recent trial do and do not show.
GLP-1 drugs and the ocular surface
A 2026 review links GLP-1 drugs to possible ocular-surface repair and changes around the eye, but human evidence remains small and observational.
GLP-1 Drugs and OSA Complication Risk
A five-year database study linked GLP-1 drugs to fewer lung complications in people with sleep apnea and type 2 diabetes, without proving causation.
GLP-1 drugs and sleep apnea outcomes
A matched US database study links GLP-1 drug use in sleep apnea with fewer strokes, hospital visits and deaths, but it cannot prove cause and effect.
Pediatric GLP-1 Review: Effects and Safety
A 2026 systematic review links pediatric GLP-1 medicines with lower BMI or HbA1c, while highlighting gastrointestinal effects and long-term gaps.
Retatrutide Results and the 25% Finding
A phase 3 retatrutide trial reported mean body-weight change of 25.0% at 80 weeks in one study group. Here is what that result does and does not show.
Peptides before shoulder replacement
What human evidence and surgical guidance can say about TB-500, BPC-157, and other peptides before shoulder replacement.
Tirzepatide Reports in EudraVigilance
A 2026 analysis of tirzepatide reports in EudraVigilance found reporting patterns, not individual risks or proof of causation.
How Tirzepatide May Raise Heart Rate
A human stem-cell study links tirzepatide to faster pacemaker-cell beating through cAMP and calcium signalling, but it is not a patient trial.
Tirzepatide and Male Fertility
A 2026 review finds a plausible research question around tirzepatide and male reproductive health, but direct human fertility evidence remains limited.
What a 2026 obesity-drug review found
A 2026 scoping review found the largest weight-loss results with incretin-based obesity medicines, while long-term questions remain.
Dual GLP-1/glucagon agonists: review
A 2026 review finds dual GLP-1/glucagon agonists reduce weight in trials, while separating them from retatrutide's three-receptor profile.